Anavex Life Sciences Corp (AVXL)

[Investor2014]

Exception on 4 & 5.

4. No, the genetic findings will be input to the Ariana KEM analysis. They are not a standalone replacement decision set.

5. Not quite, they are aiming to select upfront a patient group with higher likelihood of efficacy as opposed to data mining for a glimmer of hope post hoc like BP have been doing.